BioSpace News Archive

The agreement is part of Exelixis’ ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially available compounds, cabozantinib and cobimetinib.

The trial’s primary endpoint, the reduction in the patient-reported visual analog scale (VAS) for pain at Week 8, showed a robust impact on pain, with a greater than 50% reduction for patients treated with RT002.

Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets

The Company expects fourth quarter 2017 revenue to be approximately $272M and full year 2017 revenue to be approximately $1,030M and in line with the guidance provided on Oct 24, 2017.

On January 2, 2018, the FDA removed all drug establishments that did not renew their FDA registrations for 2018 from its active registration database. [08-January-2018] HAMPTON, Va., Jan. 8, 2018 /PRNewswire/ -- On January 2, 2018, the U.S. Food and Drug Administration (FDA) removed all drug establishments that did not renew their FDA reg

Otlertuzumab is a monospecific antibody targeting CD37 that was built on Aptevo’s ADAPTIR modular protein therapeutic platform.

The RCIGM is pleased to announce that six influential life science researchers have been recruited to serve on the Institute’s inaugural Scientific Advisory Board.

The company plans to initiate a Phase 1 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of voruciclib in patients with B-cell malignancies.

Zynex updates its Fourth Quarter Revenue Estimate to between $7.5 and $8M.

Tandem Diabetes Care today reported the successful completion of the first pilot study using a hybrid closed loop system featuring its t:slim X2 Insulin Pump with embedded algorithms from TypeZero Technologies and integration with Dexcom® G6 Continuous Glucose Monitoring (CGM).